Login to Your Account

Genentech, XOMA See Positive Long-Term Psoriasis Results

By Kim Coghill

Monday, August 5, 2002
Genentech Inc. and XOMA Ltd. said preliminary data from a long-term study of their psoriasis drug indicates that most patients who complete one year of therapy maintain a 50 percent or greater improvement in their condition. (Bioworld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription